ValuEngine Lowers Cue Biopharma (NASDAQ:CUE) to Hold

Share on StockTwits

ValuEngine cut shares of Cue Biopharma (NASDAQ:CUE) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, ValuEngine reports.

Separately, Robert W. Baird started coverage on shares of Cue Biopharma in a report on Thursday, July 25th. They issued an outperform rating and a $13.00 target price on the stock.

Shares of CUE opened at $8.82 on Tuesday. Cue Biopharma has a one year low of $4.16 and a one year high of $9.94. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.19. The company’s fifty day moving average price is $8.16 and its 200 day moving average price is $8.03.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.10. The firm had revenue of $1.06 million for the quarter. Cue Biopharma had a negative net margin of 2,039.41% and a negative return on equity of 151.93%. As a group, equities analysts predict that Cue Biopharma will post -1.96 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in CUE. BNP Paribas Arbitrage SA raised its holdings in Cue Biopharma by 1,159.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,805 shares of the company’s stock worth $29,000 after acquiring an additional 3,503 shares during the period. Strs Ohio raised its holdings in Cue Biopharma by 500.0% in the 2nd quarter. Strs Ohio now owns 15,000 shares of the company’s stock worth $134,000 after acquiring an additional 12,500 shares during the period. Sigma Planning Corp raised its holdings in Cue Biopharma by 13.6% in the 2nd quarter. Sigma Planning Corp now owns 47,805 shares of the company’s stock worth $430,000 after acquiring an additional 5,706 shares during the period. Northern Trust Corp raised its holdings in Cue Biopharma by 2.0% in the 2nd quarter. Northern Trust Corp now owns 204,555 shares of the company’s stock worth $1,839,000 after acquiring an additional 3,970 shares during the period. Finally, BlackRock Inc. raised its holdings in Cue Biopharma by 21.3% in the 2nd quarter. BlackRock Inc. now owns 1,148,126 shares of the company’s stock worth $10,321,000 after acquiring an additional 201,986 shares during the period. Hedge funds and other institutional investors own 19.93% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Read More: Management Fee

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

N Brown Group  Rating Reiterated by Shore Capital
N Brown Group Rating Reiterated by Shore Capital
Dunelm Group’s  Neutral Rating Reaffirmed at UBS Group
Dunelm Group’s Neutral Rating Reaffirmed at UBS Group
JPMorgan Chase & Co. Raises Halma  Price Target to GBX 1,500
JPMorgan Chase & Co. Raises Halma Price Target to GBX 1,500
Liberum Capital Increases Gocompare.Com Group  Price Target to GBX 145
Liberum Capital Increases Gocompare.Com Group Price Target to GBX 145
Schneider National  Cut to “Hold” at Stifel Nicolaus
Schneider National Cut to “Hold” at Stifel Nicolaus
Stantec  Upgraded by Zacks Investment Research to “Hold”
Stantec Upgraded by Zacks Investment Research to “Hold”


© 2006-2019 Ticker Report